FDA panel to discuss NPS's Natpara

FDA's Endocrinologic and Metabolic Drug Products Advisory Committee will meet on Sept. 12 to discuss a BLA from NPS Pharmaceuticals Inc. (NASDAQ:NPSP) for Natpara to treat hypoparathyroidism. The PDUFA date is Oct. 24. The product is a recombinant human parathyroid hormone 1-84 (PTH). ...